{
    "nctId": "NCT02134977",
    "briefTitle": "Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: \"QOL Survey in Premenopausal Breast Cancer Patients\"",
    "officialTitle": "Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: \"QOL Survey in Premenopausal Breast Cancer Patients\"",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2816,
    "primaryOutcomeMeasure": "Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) Total and Subscale Score at Baseline",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Premenopausal breast cancer participants who meet all the following criteria are to be enrolled in the surveillance:\n\n  1. Participants who received 4 weeks of treatment with a repository LH-RHa preparation within 1 week prior to administration of Leuplin SR 11.25 mg Injection Kit.\n  2. Participants receiving Leuplin SR 11.25 mg Injection Kit as adjuvant therapy.\n  3. Participants with performance status grade of 0 or 1.\n  4. Participants who answered all of the questions on the \"QOL check sheet (I)\" at the start (Week 0) of treatment with Leuplin SR 11.25 mg Injection Kit.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria are to be excluded from the surveillance:\n\n  1. Participants with a history of hypersensitivity to ingredient(s) in Leuplin SR 11.25 mg Injection Kit or synthetic derivatives of luteinizing hormone-releasing hormone (LH-RH) or LH-RH.\n  2. Pregnant women, possibly pregnant women, and nursing mothers.\n  3. Participants with advanced (T4 or M1 according to the TNM classification \\[General Rules for Clinical and Pathological Recording of Breast Cancer: 16th edition\\]) or recurrent breast cancer.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}